Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy-Reference-Cited by-同舟云学术

Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy

Published:2019-03-24 Issue:5 Volume:13 Page:272-279
ISSN:1752-6981
Container-title:The Clinical Respiratory Journal
language:en
Short-container-title:Clin Respir J

Author:

Murthy Vivek¹^ORCID,Katzman Daniel¹,Sterman Daniel H.¹^ORCID

Affiliation:

1. NYU Pulmonary Oncology Research Team (NYU PORT), Division of Pulmonary, Critical Care, and Sleep Medicine NYU School of Medicine, NYU Langone Health New York New York

Funder

Mesothelioma Applied Research Foundation

Publisher

Wiley

Subject

Genetics(clinical),Pulmonary and Respiratory Medicine,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/crj.13010

Reference41 articles.

1. Pleural effusions as markers of mortality and disease severity

2. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

3. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

4. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

5. Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of intrapleural perfusion with hyperthermic chemotherapy for malignant pleural effusion: a meta-analysis;Journal of Cardiothoracic Surgery;2024-05-06

2. Case report: Envafolimab combined with Endostar in the treatment of advanced non-small cell lung cancer with malignant pleural effusion;Frontiers in Oncology;2024-04-04

3. Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma;Lung Cancer;2023-11

4. Malignant Pleural Effusions in the Era of Immunotherapy and Antiangiogenic Therapy;Seminars in Respiratory and Critical Care Medicine;2023-06-12

5. Locoregional delivery of CAR-T cells in the clinic;Pharmacological Research;2022-08